A Comprehensive Review of Treprostinil Pharmacokinetics Via Four Routes of Administration

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2016 Jun 12

PMID 27286723

Citations 27

Authors

Parag Kumar

Emily Thudium

Kevin Laliberte

David Zaccardelli

Andrew Nelsen

Affiliations

Soon will be listed here.

Abstract

Treprostinil is available in three different formulations and four different routes of administration: Remodulin (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso (treprostinil sodium, inhaled administration), and Orenitram (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). Pharmacokinetic studies have been performed in healthy volunteers and patients with PAH. The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH.

Citing Articles

Treatment algorithm for pulmonary arterial hypertension.

Chin K, Gaine S, Gerges C, Jing Z, Mathai S, Tamura Y Eur Respir J. 2024; 64(4).

PMID: 39209476 PMC: 11525349. DOI: 10.1183/13993003.01325-2024.

Quantification of treprostinil concentration in rat and human using a novel validated and rapid liquid chromatography-tandem mass spectrometry method: Experimental and clinical applications in ischemia-reperfusion injury.

Gallucci G, Agbabiaka M, Ding M, Gohh R, Ghonem N Clin Chim Acta. 2024; 561:119837.

PMID: 38945284 PMC: 11246794. DOI: 10.1016/j.cca.2024.119837.

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy.

Steinbacher D, Murray B, Devlin T, Carson S, Ford H Pulm Circ. 2024; 14(2):e12396.

PMID: 38854955 PMC: 11157496. DOI: 10.1002/pul2.12396.

Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy.

Perez V, Williams V, Rahaghi F Cureus. 2024; 16(2):e54184.

PMID: 38500893 PMC: 10948086. DOI: 10.7759/cureus.54184.

Recent Advances in the Treatment of Interstitial Lung Diseases.

Bang A, Bang S, Bang A, Acharya S, Shukla S Cureus. 2023; 15(10):e48016.

PMID: 38034229 PMC: 10687490. DOI: 10.7759/cureus.48016.

References

Jenkins A, Wang-Smith L, Marbury T, Laliberte K . Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. J Cardiovasc Pharmacol. 2012; 61(4):272-6. DOI: 10.1097/FJC.0b013e31827e0fa9. View

Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S . Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006; 48(8):1672-81. DOI: 10.1016/j.jacc.2006.06.062. View

McLaughlin V, Benza R, Rubin L, Channick R, Voswinckel R, Tapson V . Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55(18):1915-22. DOI: 10.1016/j.jacc.2010.01.027. View

Channick R, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin L . Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006; 48(7):1433-7. DOI: 10.1016/j.jacc.2006.05.070. View

Gotzkowsky S, Dingemanse J, Lai A, Mottola D, Laliberte K . Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010; 50(7):829-34. DOI: 10.1177/0091270009351173. View

Peterson L, Marbury T, Marier J, Laliberte K . An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. J Clin Pharm Ther. 2013; 38(6):518-23. DOI: 10.1111/jcpt.12094. View

Bourge R, Tapson V, Safdar Z, Benza R, Channick R, Rosenzweig E . Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2012; 31(1):38-44. PMC: 3561685. DOI: 10.1111/1755-5922.12008. View

Benza R, Seeger W, McLaughlin V, Channick R, Voswinckel R, Tapson V . Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011; 30(12):1327-33. DOI: 10.1016/j.healun.2011.08.019. View

Wade M, Baker F, Roscigno R, DellaMaestra W, Arneson C, Hunt T . Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004; 44(5):503-9. DOI: 10.1177/0091270004264638. View

10.

Bourge R, Waxman A, Gomberg-Maitland M, Shapiro S, Tarver 3rd J, Zwicke D . Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016; 150(1):27-34. DOI: 10.1016/j.chest.2015.11.005. View

11.

Barst R, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C . Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006; 28(6):1195-203. DOI: 10.1183/09031936.06.00044406. View

12.

Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M . Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004; 44(2):209-14. DOI: 10.1097/00005344-200408000-00010. View

13.

Wade M, Hunt T, Lai A . Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol. 2003; 41(6):908-15. DOI: 10.1097/00005344-200306000-00012. View

14.

Lim A, Wang-Smith L, Kates J, Laurent A, Kumar P, Laliberte K . The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers. J Clin Pharm Ther. 2013; 38(6):450-5. DOI: 10.1111/jcpt.12085. View

15.

McLaughlin V, Archer S, Badesch D, Barst R, Farber H, Lindner J . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American.... J Am Coll Cardiol. 2009; 53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. View

16.

Gotzkowsky S, Kumar P, Mottola D, Laliberte K . Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. J Cardiovasc Pharmacol. 2013; 61(5):444-51. DOI: 10.1097/FJC.0b013e3182893d90. View

17.

White R, Torres F, Allen R, Jerjes C, Pulido T, Yehle D . Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2013; 61(6):474-81. DOI: 10.1097/FJC.0b013e31828685da. View

18.

Sandifer B, Brigham K, Lawrence E, Mottola D, Cuppels C, Parker R . Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol (1985). 2005; 99(6):2363-8. DOI: 10.1152/japplphysiol.00083.2005. View

19.

Jing Z, Parikh K, Pulido T, Jerjes-Sanchez C, White R, Allen R . Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127(5):624-33. DOI: 10.1161/CIRCULATIONAHA.112.124388. View

20.

Falcetti E, Hall S, Phillips P, Patel J, Morrell N, Haworth S . Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 182(9):1161-70. PMC: 3001258. DOI: 10.1164/rccm.201001-0011OC. View